Q4 EPS Estimate for Fresenius Medical Care Raised by Analyst

Fresenius Medical Care AG (NYSE:FMS) – Zacks Research boosted their Q4 2026 earnings estimates for shares of Fresenius Medical Care in a report released on Monday, December 30th. Zacks Research analyst I. Bandyopadhyay now expects that the company will earn $0.62 per share for the quarter, up from their prior estimate of $0.61. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.55 per share.

Several other research analysts also recently commented on FMS. StockNews.com started coverage on Fresenius Medical Care in a report on Friday. They issued a “strong-buy” rating on the stock. Truist Financial boosted their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $24.30.

Fresenius Medical Care Stock Performance

Fresenius Medical Care stock opened at $22.38 on Thursday. The firm has a fifty day simple moving average of $22.21 and a two-hundred day simple moving average of $20.64. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care has a twelve month low of $17.93 and a twelve month high of $24.31. The company has a market capitalization of $13.13 billion, a PE ratio of 18.50, a P/E/G ratio of 0.96 and a beta of 0.93.

Hedge Funds Weigh In On Fresenius Medical Care

Hedge funds have recently made changes to their positions in the business. Allworth Financial LP lifted its stake in Fresenius Medical Care by 53.1% in the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after acquiring an additional 581 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Fresenius Medical Care in the 3rd quarter worth about $38,000. GAMMA Investing LLC boosted its stake in shares of Fresenius Medical Care by 50.4% during the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after purchasing an additional 1,675 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in shares of Fresenius Medical Care during the third quarter valued at about $112,000. Finally, Venturi Wealth Management LLC raised its stake in Fresenius Medical Care by 1,045.8% in the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after buying an additional 4,800 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.